相关实验视频
Updated: Sep 8, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
在多克索鲁比辛后,布利祖马布和伦瓦提尼布联合引起的左心室功能障碍:哪种药物是罪祸首?
Yoshihide Ishikawa1, Masataka Suzuki1, Eri Konda2
1Department of Cardiology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
JACC. Case reports
|September 5, 2025
概括
鉴定多种化疗的心脏毒性是复杂的. 这一案例表明免疫检查点抑制剂和向治疗如何导致心力衰竭,强调安全癌症治疗的多学科评估.
科学领域:
- 癌症学
- 心脏病学
- 药理学
背景情况:
- 组合化疗方案可以改善癌症的结果,但在识别特定心脏毒剂方面存在挑战.
- 同时开始多种化疗复杂化了药物诱导心脏毒性的诊断.
- 心脏毒性是癌症治疗的一个重要问题,可能导致严重的心脏功能障碍.
研究的目的:
- 突出在多种化疗药物同时使用时发现心脏毒性的诊断挑战.
- 在患有子宫内膜癌的患者中研究勃利祖马布,伦瓦替尼和多克索鲁比辛的潜在重叠心脏毒性机制.
- 强调多学科合作在治疗化疗引起的心脏毒性的重要性.
主要方法:
- 一名58岁的子宫内膜癌患者的病例报告,接受了多克索鲁比辛治疗,随后接受了潘布罗利祖马布和伦瓦提尼布治疗.
- 心脏磁共振成像 (CMR) 和心脏内膜活检以评估心脏功能和病理.
- 停药后心脏功能恢复的分析和随后的布罗利祖马布单一治疗.
主要成果:
- 患者患有心力衰竭,排泄率降低 (26%) 归因于急性心肌炎.
- 心脏内膜活检显示间歇性纤维化和T淋巴细胞透,没有肌细胞亡.
- 在不使用类固醇的情况下,停用勃利祖马布和伦瓦替尼导致左心室功能恢复.
- 对肺转移的勃利祖马布单一治疗恢复是可以容忍的.
结论:
- 这一案例强调需要区分心脏毒性机制,包括免疫检查点抑制剂诱导的心肌炎和可逆心脏毒性与向药物.
- 观察到布罗利祖马布,伦瓦提尼布和先前的多克索鲁比辛治疗可能会导致心脏毒性.
- 多学科讨论对于疑似心脏毒性化疗的准确诊断和管理至关重要,包括考虑重新使用免疫检查点抑制剂.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:29Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
25
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
25
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:26Heart Failure Drugs: Inotropic Agents
716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716